Proposed Update of the CDC's 2006 Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings; Re-opening of the Comment Period, 25452-25453 [2020-09348]
Download as PDF
<![CDATA[
25452
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices
(HAMP) Workgroup, NIOSH Miner
Health Program strategic plan, NIOSH
Mining respirable crystalline silica
research, Understanding elongate
mineral particle exposure in mining,
Research roadmap for haul truck health
and safety issues, and Future of the coal
industry presentation. The meeting will
also include an update from the NIOSH
Associate Director for Mining. Agenda
items are subject to change as priorities
dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09306 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Advisory Committee on Breast Cancer
in Young Women (ACBCYW);
Cancellation of Meeting
Notice is hereby given of a change in
the meeting of the Advisory Committee
on Breast Cancer in Young Women
(ACBCYW); May 13, 2020, 8:00 a.m. to
1:00 p.m., EDT.
The teleconference and web
conference, which was published in the
Federal Register on March 16, 2020,
Volume 85, Number 51, page 14945, is
being canceled in its entirety.
FOR FURTHER INFORMATION CONTACT:
Jeremy McCallister, Designated Federal
Officer, National Center for Chronic
Disease Prevention and Health
Promotion, CDC, 4770 Buford Hwy. NE,
Mailstop S107–4, Atlanta, Georgia
30341, Telephone (404) 639–7989, Fax
(770) 488–4760; Email: acbcyw@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
08:07 May 01, 2020
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09305 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2019–0069]
Proposed Update of the CDC’s 2006
Revised Recommendations for HIV
Testing of Adults, Adolescents, and
Pregnant Women in Health-Care
Settings; Re-opening of the Comment
Period
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the reopening of this docket to obtain
additional public comment on the
proposed update of the 2006 Revised
Recommendations for HIV Testing. CDC
is re-opening this docket at the request
of the public.
DATES: Electronic or written comments
must be received by June 30, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2019–
0069, by any of the following methods
below. CDC does not accept public
comment by email.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: DHAP Guideline Team,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE, MS
US8–4, Atlanta, Georgia 30329.
FOR FURTHER INFORMATION CONTACT:
Priya Jakhmola, Health Scientist,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
US8–4, Atlanta, Georgia 30329.
Telephone: 404–639–2495, Email:
dhapguideline@cdc.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Prevention and the Agency for Toxic
Substances and Disease Registry.
Jkt 250001
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data related to HIV screening
approaches. In addition, CDC invites
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
comments specifically on opt-out
routine HIV testing, including, but not
limited to:
• Suggestions for revisions, edits, and
new additions
• Contemporary issues and new
evidence
• Implementation barriers, challenges,
and lessons learned
• Examples of innovative models,
partnerships, and collaborations
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comments or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information,
inappropriate language, or examples of
a mass-mail campaign. CDC will
carefully consider all comments
submitted in preparation of the final
document and may revise the final
document as appropriate.
Background
On August 30, 2019, CDC published
a notice (84 FR 45495) announcing the
availability of a Proposed Update of the
CDC’s 2006 Revised Recommendations
for HIV Testing of Adults, Adolescents,
and Pregnant Women in Health-Care
Settings. The comment period ended
October 28, 2019. CDC received a
request from the public to re-open the
comment period.
The CDC guideline ‘‘Revised
Recommendations for HIV Testing of
Adults, Adolescents, and Pregnant
Women in Health-Care Settings’’ was
published on September 22, 2006 in
CDC’s Morbidity and Mortality Weekly
Report (MMWR). Since then, there have
been changes in evidence related to HIV
testing technologies and interventions,
disease epidemiology, outcomes,
implementation resources, and related
guidelines. This evidence will be
identified, assessed, and analyzed to
inform the update of the guideline.
CDC will update the 2006 guideline
based on input from subject matter
experts, public health agencies, the
public, and other stakeholders. The
guideline development process will
draw on up-to-date nationally and
internationally accepted guideline
E:\FR\FM\01MYN1.SGM
01MYN1
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices
development criteria, tools, and
resources, including CDC guideline
development standards. The process
will include a rigorous systematic
review of key questions formulated
through the PICO (Patient-InterventionComparator-Outcome) method. PICO is
the foundation of an evidence-based
process and facilitates the search for
relevant evidence by identifying key
concepts and formulating a search
strategy. Graded recommendations will
be developed using quality and strength
of underlying evidence.
Throughout the process of updating
the guideline, there will be multiple
opportunities for the public to comment
on the drafts. We welcome input from
a diverse range of perspectives, which
will inform the development of the
guideline, improve its credibility, and
increase the transparency of the process.
Dated: April 28, 2020.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2020–09348 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request; Information Collection
Request Title: Bureau of Health
Workforce Substance Use Disorder
Evaluation, OMB No. 0906–xxxx–NEW
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995,
HRSA has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period. OMB may act on
HRSA’s ICR only after the 30 day
comment period for this Notice has
closed.
DATES: Comments on this ICR should be
received no later than June 1, 2020.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
SUMMARY:
VerDate Sep<11>2014
08:07 May 01, 2020
Jkt 250001
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email Lisa
Wright-Solomon, the HRSA Information
Collection Clearance Officer at
paperwork@hrsa.gov or call (301) 443–
1984.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
Bureau of Health Workforce Substance
Use Disorder (SUD) Evaluation, OMB
No. 0906–xxxx–New.
Abstract: In September 2017, HRSA’s
Bureau of Health Workforce launched a
multi-part effort to increase the
workforce capacity of the U.S. health
care system to prevent and treat the
opioid crisis. As a part of this effort,
HRSA developed or expanded activities
under five programs to help combat the
crisis: (1) The National Health Service
Corps (NHSC) Loan Repayment Program
offers loan repayment to providers
focused on Substance Use Disorder
treatment (NHSC SUD Workforce Loan
Repayment Program (LRP)); (2) the
National Health Service Corps Rural
Communities Loan Repayment Program
(NHSC Rural Communities LRP); (3) the
Opioid Workforce Expansion Program
(OWEP); (4) the Behavioral Health
Workforce Education and Training
Program (BHWET); and (5) the Graduate
Psychology Education (GPE) Program.
These programs provide either loan
repayment to providers (NHSC SUD
Workforce LRP, NHSC Rural
Communities LRP), or funding for
training programs for behavioral health
professionals and paraprofessionals to
increase integrated behavioral health
into primary care treatment and
interprofessional team-based care to
high-need areas (OWEP, BHWET, GPE).
The purpose of the planned
evaluation is to assess these programs
with respect to their stated goals of
increasing access to the number of
clinicians delivering evidence-based
SUD treatment, enhancing education
and training in substance use
prevention and treatment for current
and future health care professionals and
paraprofessionals in rural and
underserved communities, and
integrating behavioral health into
primary care to improve the capacity of
the health care delivery system to
provide SUD prevention and treatment
services.
The evaluation will include data
collection through web-based surveys to
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
25453
trainees, recipients of loan repayments,
grantee organizations, and training sites
participating in HRSA’s SUD prevention
and treatment programs. At the trainee/
participant level, questions will focus
on educational and professional
background; motivation and incentives
to join or leave the program; training
experiences; perceived readiness to
deliver SUD treatment services (where
applicable); capacity to engage in
prevention strategies; and postgraduation employment (where
applicable). At the recipient grantee
organization level (note: This level is not
relevant to the NHSC programs),
questions will focus on recruitment and
retention of students, how their SUD
prevention and treatment training
program curriculum was developed, as
applicable, collaboration with SUD
prevention and treatment training sites,
plans for sustainability of SUD
prevention and treatment activities, as
well as any other benefits that resulted
from the program. At the site level,
questions will focus on SUD prevention
and treatment training such as
addressing motivation for the site to
participate, whether and what type of
integrated care delivery is available, and
other organizational factors of the site.
At all three levels, and for all programs,
we will collect survey SUD prevention
and treatment training data on
satisfaction with the program and
recommendations for improving it.
In total, six survey instruments will
be used in this evaluation: (1) NHSC
SUD Workforce Loan Repayment
Program/NHSC Rural Communities
Loan Repayment Program/NHSC Loan
Repayment Program—Participant
Survey; (2) NHSC Loan Repayment
Program— Site Survey; (3) Grantee
Training and Educational Programs—
Trainee Survey; (4) Grantee Training
and Educational Programs—Alumni
Survey; (5) Grantee Training and
Educational Programs—Site Survey; and
(6) Grantee Training and Educational
Programs—Grantee Organization
Survey. As part of a comprehensive
questionnaire design process, questions
will be limited and refined to collect
information not available through
secondary sources. Any data collected
will not be duplicative of that collected
under progress reports or other HRSA
grant monitoring. NHSC site and
participant survey questions will be
drawn from prior NHSC Satisfaction
Surveys, which were fielded in 2017
and 2018 but were discontinued. Skip
patterns will allow respondents to
answer only relevant questions for each
of their programs. Participation in all
surveys is voluntary, and all surveys
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 85, Number 85 (Friday, May 1, 2020)]
[Notices]
[Pages 25452-25453]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09348]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2019-0069]
Proposed Update of the CDC's 2006 Revised Recommendations for HIV
Testing of Adults, Adolescents, and Pregnant Women in Health-Care
Settings; Re-opening of the Comment Period
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) in the
Department of Health and Human Services (HHS) announces the re-opening
of this docket to obtain additional public comment on the proposed
update of the 2006 Revised Recommendations for HIV Testing. CDC is re-
opening this docket at the request of the public.
DATES: Electronic or written comments must be received by June 30,
2020.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0069, by any of the following methods below. CDC does not accept public
comment by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: DHAP Guideline Team, Centers for Disease Control and
Prevention, 1600 Clifton Road, NE, MS US8-4, Atlanta, Georgia 30329.
FOR FURTHER INFORMATION CONTACT: Priya Jakhmola, Health Scientist,
Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS
US8-4, Atlanta, Georgia 30329. Telephone: 404-639-2495, Email:
[email protected].
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data related to HIV
screening approaches. In addition, CDC invites comments specifically on
opt-out routine HIV testing, including, but not limited to:
Suggestions for revisions, edits, and new additions
Contemporary issues and new evidence
Implementation barriers, challenges, and lessons learned
Examples of innovative models, partnerships, and
collaborations
Please note that comments received, including attachments and other
supporting materials, are part of the public record and are subject to
public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your
comments or supporting materials that you consider confidential or
inappropriate for public disclosure. If you include your name, contact
information, or other information that identifies you in the body of
your comments, that information will be on public display. CDC will
review all submissions and may choose to redact, or withhold,
submissions containing private or proprietary information,
inappropriate language, or examples of a mass-mail campaign. CDC will
carefully consider all comments submitted in preparation of the final
document and may revise the final document as appropriate.
Background
On August 30, 2019, CDC published a notice (84 FR 45495) announcing
the availability of a Proposed Update of the CDC's 2006 Revised
Recommendations for HIV Testing of Adults, Adolescents, and Pregnant
Women in Health-Care Settings. The comment period ended October 28,
2019. CDC received a request from the public to re-open the comment
period.
The CDC guideline ``Revised Recommendations for HIV Testing of
Adults, Adolescents, and Pregnant Women in Health-Care Settings'' was
published on September 22, 2006 in CDC's Morbidity and Mortality Weekly
Report (MMWR). Since then, there have been changes in evidence related
to HIV testing technologies and interventions, disease epidemiology,
outcomes, implementation resources, and related guidelines. This
evidence will be identified, assessed, and analyzed to inform the
update of the guideline.
CDC will update the 2006 guideline based on input from subject
matter experts, public health agencies, the public, and other
stakeholders. The guideline development process will draw on up-to-date
nationally and internationally accepted guideline
[[Page 25453]]
development criteria, tools, and resources, including CDC guideline
development standards. The process will include a rigorous systematic
review of key questions formulated through the PICO (Patient-
Intervention-Comparator-Outcome) method. PICO is the foundation of an
evidence-based process and facilitates the search for relevant evidence
by identifying key concepts and formulating a search strategy. Graded
recommendations will be developed using quality and strength of
underlying evidence.
Throughout the process of updating the guideline, there will be
multiple opportunities for the public to comment on the drafts. We
welcome input from a diverse range of perspectives, which will inform
the development of the guideline, improve its credibility, and increase
the transparency of the process.
Dated: April 28, 2020.
Sandra Cashman,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2020-09348 Filed 4-30-20; 8:45 am]
BILLING CODE 4163-18-P
